A review of current and future treatment options in renal cancer

American Journal of Cancer

Volumn 2, Issue 3, 2003, Pages 201-210

  Vaishampayan, Ulka ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYTOTOXIC AGENT; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CYTOTOXICITY; DISEASE ASSOCIATION; DOSE RESPONSE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MENTAL DISEASE; METASTASIS; MORTALITY; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; RISK FACTOR; SEPSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 0037696880     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302030-00004     Document Type: Review

References (84)

1. Mydlo JH. Growth factors and renal cancer: characterization and therapeutic implications. World J Urol 1995; 13 (6): 356-63
2. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52 (1): 23-47
3. Mufti GR, Gove JR, Badenoch DF, et al. Transitional cell carcinoma of the renal pelvis and ureter. Br J Urol 1989; 63: 135-40
4. Phillips JL, Pavlovich CP, Walther M, et al. The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. Curr Opin Urol 2001; 11: 463-9
5. Childs R, Chernoff A, Contenin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8
6. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2h compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9
7. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial: European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Lancet 2001; 358: 966-70
8. Yu MC, Mack TM, Hanisch R, et al. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors renal cell carcinoma. J Natl Cancer Inst 1986; 77: 351-6
9. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 1990; 69: 217-26
10. Armstrong B, Garrod A, Doll R. A retrospective study of renal cancer with special reference to coffee and animal protein consumption. Br J Cancer 1976; 33 (2): 127-36
11. McLaughlin JK, Gao YT, Gao RN, et al. Risk factors for renal-cell cancer in Shanghai, China. Int J Cancer 1992; 52: 562-5
12. Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell cancer. Am J Epidemiol 1986; 124: 926-41
13. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-31
14. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63
15. Tsui KH, Shvarts O, Smith RB, et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000; 163: 426-30
16. Friedrich CA. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 2001; 10: 763-7
17. Hes FJ, van der Luijt RB, Lips CJ. Clinical management of Von Hippel-Lindau (VHL) disease. Neth J Med 2001; 59: 225-34
18. Arbiser JL, Brat D, Hunter S, et al. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol 2002; 46: 376-80
19. Eble JN. Angiomyolipoma of kidney. Semin Diagn Pathol 1998; 15: 21-40
20. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181: 125-43
21. Hughson MD, Johnson LD, Silva FG, et al. Nonpapillary and papillary renal cell carcinoma: a cytogenetic and phenotypic study. Mod Pathol 1993; 6: 449-56
22. Delahunt B. Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology 1999; 31: 185-90
23. Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma: a treatable entity. Cancer 1987; 60: 1313-8
24. Chao D, Zisman A, Pantuck AJ, et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002; 167: 71-4
25. Figenshau RS, Basler JW, Ritter JH, et al. Renal medullary carcinoma. J Urol 1998; 159: 711-3
26. Stahlschmidt J, Cullinane C, Roberts P, et al. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol 1999; 33: 551-7
27. Belldegrun A, Tsui KH. deKernion JB, et al. Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 1999; 17: 2868-75
28. D'Armiento M, Damiano R, Feleppa B, et al. Elective conservative surgery for renal carcinoma versus radical nephrectomy: a prospective study. Br J Urol 1997; 79: 15-9
29. Green FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging handbook. 6th ed. New York: Springer Verlag, 2002: 355-60
30. Gelb AB, Shibuya RB, Weiss LM, et al. Stage I renal cell carcinoma: a clinicopathologic study of 82 cases. Am J Surg Pathol 1993; 17: 275-86
31. Vasselli JR, Yang JC, Linchan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166: 68-72
32. Johnson DE, Kaesler KE, Samuels ML. Is nephrectomy justified in patients with metastatic renal carcinoma? J Urol 1975; 114: 27-9
33. Flanigan RC. The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression. Urol Clin North Am 1987; 14: 757-62
34. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40
35. Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-35
36. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3: 475-80
37. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001; 345: 1711-2
38. Flanigan RC. Role of surgery in metastatic renal cell carcinoma. Semin Urol 1989; 7: 191-4
39. Pizzocaro G, Piva L, Mapelli S, et al. Surgical treatment of distant metastases in renal cell carcinoma. Arch Ital Urol Nefrol Androl 1991; 63: 245-8
40. Langer W, Hofmockel G, Theiss M, et al. Surgical treatment of metastases in renal cell carcinoma. Urologe A 1997; 36: 548-51
41. Dernevik L, Berggren H, Larsson S, et al. Surgical removal of pulmonary metastases from renal cell carcinoma. Scand J Urol Nephrol 1985; 19 (2): 133-7
42. Gotoh A, Mizuno Y, Gohji K, et al. Clinical study on surgical treatment of renal cell carcinoma with pulmonary metastases. Hinyokika Kiyo 1992; 38: 753-7
43. Dineen MK, Pastore RD, Emrich LJ, et al. Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 1988; 140: 277-9
44. Chatziioannou AN, Johnson ME, Pneumaticos SG, et al. Preoperative embolization of bone metastases from renal cell carcinoma. Eur Radiol 2000; 10: 593-6
45. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425-31
46. Gleave M, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338: 1265-71
47. Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999 17: 2859-2867
48. Ramp U, Dejosez M, Mahotka C, et al. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma. Br J Cancer 2000; 82: 1851-9
49. Reinecke P, Schmitz M, Schneider EM, et al. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types. Cancer Invest 2000; 18: 614-25
50. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19: 1541-3
51. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-17
52. Mertens WC, Eisenhauer EA, Jolivet J, et al. Docetaxel in advanced renal carcinoma: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 185-7
53. Einzig AI, Gorowski E, Sasloff J, et al. Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 1991; 9: 133-6
54. Schomburg A, Kirchner H, Fenner M, et al. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur J Cancer 1993; 29A (5): 737-40
55. Law TM, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 1994; 12: 143-5
56. Casali M, Marcellini M, Casali A, et al. Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study. J Exp Clin Cancer Res 2001; 20: 195-8
57. Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419-26
58. Oevermann K, Buer J, Hoffmann R, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000; 83: 583-7
59. Atzpodien J, Kirchner H, Hanninen EL, et al. Interleukin-2 in combination with interferon alpha and 5-flourouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A Suppl. 5: S6-8
60. Hanninen EL, Fenner M, Kirchner H, et al. Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma. Cancer Biother 1993; 8 (4): 301-6
61. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin-2, interferon alpha and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6: 3442-50
62. Atzpodien J, Kirchner H, Duensing S, et al. Biochemotherapy of advanced metastatic renal cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-flourouracli, vinblastine, and 13-cis-retinoic acid. World J Urol 1995; 13: 174-7
63. Vaishampayan U, Flaherty L, Du W, et al. Phase II evaluation of interferon alpha, 13-cisretinoic acid and paclitaxel in advanced renal cell carcinoma. Cancer 2001; 92: 519-23
64. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-96
65. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12: 1572-6
66. McDermott D, Flaherty L, Clark J, et al. A randomized phase III trial of high dose interleukin-2 (HDIL-2) versus subcutaneous (SC) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC) [abstract 685]. Proc Am Soc Clin Oncol 2001; 20: 172a
67. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-8
68. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-80
69. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2A and medroxyprogesterone in advanced renal cell carcinoma: a randomised trial [abstract]. Acta Oncol 1990; 29: 155-62
70. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11: 1368-75
71. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96
72. Medical Research Council Renal Cancer Collaborators. Interferon-alfa and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353: 14-7
73. Motzer RJ, Rakhit A, Ginsberg M, et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19 (5): 1312-9
74. Schwartzentruber DJ. Guidelines for the safe administration of high dose interleukin-2. J Immunother 2001; 24: 287-93
75. Palmer PA, Atzpodien J, Philip T, et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 1993; 8: 123-36
76. Atzpodien J, Kirchner H, de Mulder P, et al. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. Cancer Biother 1993; 8: 289-300
77. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824-32
78. Dillman RO, Barth NM, VanderMolen LA, et al. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm 2001; 16: 47-54
79. Rini BI, Zimmerman T, Stadler WM, et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy, feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-24
80. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002 Jan 1; 20: 302-6
81. Stebbing J, Benson C. Eisen T, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001 Sep 28; 85: 953-8
82. Eder JP, Clark JW, Supko JG, et al. A phase I pharmacokinetic and pharmacodynamic trial of recombinant human endostatin [abstract 275]. Proc Am Soc Clin Oncol 2001; 20: 70a
83. Yang JC, Haworth L, Steinberg SM, et al. A randomized double blind placebo controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer [abstract 15]. Proc Am Soc Clin Oncol 2002; 21: 5a
84. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-89